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Abstract Exosomes are extracellular vesicles that are released when endosomes fuse with the
plasma membrane. They have been implicated in various functions in both health and disease,
including intercellular communication, antigen presentation, prion transmission, and tumour cell
metastasis. Here we show that inactivating the vacuolar ATPase in HeLa cells causes a dramatic
increase in the production of exosomes, which display endocytosed tracers, cholesterol, and CD63.
The exosomes remain clustered on the cell surface, similar to retroviruses, which are attached to
the plasma membrane by tetherin. To determine whether tetherin also attaches exosomes, we
knocked it out and found a 4-fold reduction in plasma membrane-associated exosomes, with a
concomitant increase in exosomes discharged into the medium. This phenotype could be rescued
by wild-type tetherin but not tetherin lacking its GPI anchor. We propose that tetherin may play a
key role in exosome fate, determining whether they participate in long-range or short-range
interactions.
DOI: 10.7554/eLife.17180.001
Introduction
Exosomes are extracellular vesicles that have been implicated in a wide range of functions, including
intercellular communication, tumour cell migration, RNA shuttling, and antigen presentation. By defi-
nition, exosomes are derived from multivesicular endosomes or multivesicular bodies (MVBs), which
contain intralumenal vesicles (ILVs). When the MVBs fuse with the plasma membrane, the ILVs are
discharged, and the resulting extracellular vesicles are called exosomes. However, there are other
types of extracellular vesicles, such as those that are produced by shedding from the plasma mem-
brane, and at present there is no standard way of specifically purifying exosomes. Thus, some of the
functions that have been attributed to exosomes may need to be reassessed, because of the possi-
bility of contamination with other types of vesicles (Raposo and Stoorvogel, 2013).
In a recent screen for regulators of clathrin-mediated endocytosis in HeLa cells, we observed that
knocking down or inactivating the vacuolar ATPase (V-ATPase) caused the cells to produce clusters
of extracellular vesicles (Kozik et al., 2013). These vesicles had the characteristic appearance of exo-
somes, suggesting that when endosomes are unable to acidify, they have an increased tendency to
fuse with the plasma membrane (see Figure 6 in Kozik et al., 2013), a phenomenon also reported
by others (Alvarez-Erviti et al., 2011; Danzer et al., 2012). Knocking down or inhibiting the
V-ATPase also caused a block in clathrin-mediated endocytosis, and we proposed that this block
was due to a redistribution of cholesterol from the plasma membrane to an endosomal compart-
ment. Our hypothesis was supported by the finding that we could partially rescue the phenotype by
adding exogenous cholesterol to the cells. One question raised by our study was why, if cholesterol-
rich non-acidified endosomes fuse with the plasma membrane, does the plasma membrane not
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regain its cholesterol? Indeed, when we measured cell surface-associated cholesterol by light micros-
copy, using filipin as a cholesterol probe, the loss upon V-ATPase knockdown or treatment with the
V-ATPase inhibitor Bafilomycin A1 (BafA1) was only partial (~50%). In contrast, others have shown
that treating cells with methyl-b-cyclodextrin, which has a similar effect on clathrin-mediated endocy-
tosis, removes nearly all of the plasma membrane cholesterol (Rodal et al., 1999).
We initiated the present study to try to answer some of the questions posed by our previous
study. We started by quantifying the amount of plasma membrane cholesterol more precisely by
developing a method for localising cholesterol at the electron microscope level. Next, we character-
ised the extracellular vesicles that are produced when V-ATPase is inactivated, by labeling for exoso-
mal markers. Finally, we investigated why the vesicles remain aggregated and associated with the
plasma membrane instead of diffusing away.
Results
Cholesterol accumulates on extracellular vesicles following BafA1
treatment
In our previous study, we concluded that in the absence of V-ATPase activity, cholesterol accumu-
lates in endosomal compartments, based on immunofluorescence double labelling with the choles-
terol probe, filipin, and various endosomal markers (Kozik et al., 2013). To visualise these
compartments at the ultrastructural level, we used correlative light and electron microscopy (CLEM).
BafA1-treated HeLa cells (Figure 1—figure supplement 1A) were stained with filipin, imaged by
light microscopy, and then prepared for electron microscopy. The structures that stained most
intensely with filipin were found to correspond to MVBs, packed full of ILVs (Figure 1A).
So far, the only published studies showing cholesterol localisation at the electron microscope
level have been carried out using a cleaved and a biotinylated form of the toxin perfringolysin O
eLife digest Cells generally communicate with each other over short distances by direct
contact, and over long distances by releasing chemicals such as hormones. But there is also a third
way that is less well understood – small capsules or “vesicles” called exosomes can transfer
molecules from one cell to another. Exosomes are involved in the immune response and have been
linked to a number of diseases, including cancer and neurodegeneration. However, scientists are still
trying to understand how exosomes are made, what they contain and how they are released from
cells.
A common set of cells used in laboratory studies are known as HeLa cells. These cells are the
descendants of cancerous cells taken from a patient called Henrietta Lacks in 1951. When treated
with a particular drug, HeLa cells produce vesicles that look like exosomes. Yet instead of moving
freely like other exosomes, these structures stick together in clusters. This raises questions – are
these cancer cell vesicles truly exosomes? And if so, why and how are they tethered to the cell?
Using electron microscopy and biochemical tests, Edgar et al. confirm that the unusual vesicles
produced by HeLa cells are exosomes. As well as sharing characteristics with other exosomes, the
vesicles also show similarities with viruses like HIV, which attach themselves to cell surfaces and each
other using a protein called tetherin. Using a technique called gene editing to remove tetherin from
HeLa cells allowed the exosomes in the cluster to move apart.
Further investigation revealed that some cells in the immune system also produce exosome
clusters and that these clusters also contain tetherin. Edgar et al. propose that cells control whether
exosomes are involved in short-range or long-range communication by controlling the amount of
tetherin they produce.
So far, studies into the roles that exosomes play in the body have been hampered by a lack of
experimental tools. The study by Edgar et al. opens up new methods of investigation by providing
ways of altering the number of exosomes released from a cell. This should help to clarify what
exosomes do and how they work in a wide range of different cell types.
DOI: 10.7554/eLife.17180.002
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Figure 1. BafA1 treatment causes cholesterol to accumulate in intralumenal vesicles of multivesicular bodies and to be lost from the plasma membrane.
(A) HeLa cells were treated with BafA1 (100 nM, 16 hr), then fixed, stained with the cholesterol probe filipin, and prepared for correlative light and
electron microscopy (CLEM). Scale bars: 10 mm (upper) and 1 mm (lower). (B) BafA1-treated cells (100 nM, 16 hr) were stained with filipin, then
permeabilised and stained with TNM-BF. Scale bar: 20 mm. (C) Ultrathin cryosections of mock-treated and BafA1-treated HeLa cells (100 nM, 16 hr)
Figure 1 continued on next page
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(Waheed et al., 2001; Mo¨bius et al., 2002, 2003; Kwiatkowska et al., 2014). The authors of these
studies reported that in erythrocytes, lymphoblastoid cells, and platelets, cholesterol was mainly
associated with the plasma membrane, MVBs (especially ILVs), and tubular endosomes
(Mo¨bius et al., 2002). Unfortunately, the reagent they used is no longer available, and no other
techniques for EM localisation of cholesterol have been described. Recently, however, theonella-
mides (TNMs) labeled with fluorescent dyes, such as BODIPY, have been shown to be effective tools
for visualizing sterols in fixed cells by fluorescence microscopy (Nishimura et al., 2013). Because
there are BODIPY antibodies available, we reasoned that BODIPY-conjugated TNM (TNM-BF) might
be a suitable reagent for immuno-gold EM localization of cholesterol.
Double labeling fluorescence microscopy with filipin and TNM-BF showed that the two probes
have virtually identical patterns in HeLa cells, with labelling particularly concentrated in the juxtanu-
clear region (Figure 1B, Figure 1—figure supplement 1B). For electron microscopy, we labelled
cryosections of control and BafA1-treated cells with TNM-BF, followed by a commercial rabbit anti-
BODIPY antibody and protein A coupled to colloidal gold (Figure 1C). In both types of cells, we
observed strong labelling of MVBs, with gold particles particularly abundant on the ILVs (upper pan-
els), consistent with previous studies using perfringolysin O (Mo¨bius et al., 2002). In control cells,
we also saw labelling of the plasma membrane (Figure 1C, arrowheads). However, in the BafA1-
treated cells, the plasma membrane was virtually devoid of label, although there was label associ-
ated with extracellular vesicles (Figure 1C, arrows). To look specifically at cell surface cholesterol, we
performed pre-embedding labelling. Control and BafA1-treated cells were fixed and labelled with
TNM-BF followed by anti-BODIPY without permeabilisation. This method showed even more dra-
matically that cholesterol is lost from the plasma membrane following BafA1 treatment, and also
highlighted the strong labelling of extracellular vesicles (Figure 1D,E). As a control for the specificity
of labeling, we treated cells with methyl-b-cyclodextrin (MbCD), which extracts cholesterol from the
plasma membrane. We found a near-complete loss of surface labeling, although endosomes were
still labeled (Figure 1D,E, Figure 1—figure supplement 1C).
These results are largely in agreement with our previous study, in which we used filipin as a cho-
lesterol probe for light microscopy. In both cases, we found a ~50% loss of surface labeling in
BafA1-treated cells. However, in our previous study, we were unable to distinguish between the
plasma membrane and extracellular vesicles associated with the cell surface. The present study
shows that there is in fact a 15-fold loss of plasma membrane cholesterol, with a concomitant rise in
cholesterol-positive extracellular vesicles (Figure 1E).
BafA1 treatment causes an increase in exosome release
Are the cholesterol-rich extracellular vesicles that we observe in BafA1-treated cells in fact exo-
somes, or could they be plasma membrane-derived vesicles? We addressed this question in several
ways. First, exosomes have the same diameter as ILVs, i.e., 30–100 nm diameter, while other types
of extracellular vesicles are much more heterogeneous in size, often up to 1 mm in diameter. The
BafA1-induced vesicles are indistinguishable in appearance from ILVs (Figure 2A, inset left). Second,
to find out whether the vesicles come from endosomes, we carried out pulse-chase experiments
using BSA conjugated to 5 nm colloidal gold as an endocytic tracer. The cells were allowed to endo-
cytose BSA-gold for 10 min, washed, incubated for either 30 min or 4 hr to chase the gold into
endosomes or lysosomes respectively, and then treated for 16 hr with BafA1. Figure 2A shows that
Figure 1 continued
were labelled with TNM-BF and stained with rabbit anti-BODIPY followed by 10 nm protein A-gold. There is labelling both in endosomes (upper
panels) and at the cell surface (lower panels). Scale bars: 200 nm. (D) Intact mock-treated, BafA1-treated (100 nM, 16 hr), or MbCD-treated (10 mM, 30
min) HeLa cells were labelled with TNM-BF followed by anti-BODIPY and protein A-gold, revealing surface cholesterol localisation. Scale bar: 500 nm.
(E) Quantification of TNM/BF/anti-BODIPY gold labeling density for DMSO-treated, BafA1-treated (100 nM, 16 hr), or MbCD-treated (10 mM, 30 min)
cells. Graphs show mean ± S.E.M for at least 100 mm of the plasma membrane, over two independent experiments. See also Figure 1—figure
supplement 1.
DOI: 10.7554/eLife.17180.003
The following figure supplement is available for figure 1:
Figure supplement 1. Controls for specificity.
DOI: 10.7554/eLife.17180.004
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Figure 2. The extracellular vesicles that accumulate in BafA1-treated cells are exosomes. (A) HeLa cells were incubated with BSA coupled to 5 nm gold
for 10 min before being washed several times with PBS to remove any uninternalised label. The cells were then chased in full medium for either 30 min
or 4 hr to load BSA-gold into endosomes or lysosomes respectively, then treated with BafA1 (100 nM, 16 hr), fixed, and prepared for conventional EM.
Gold could be seen associated with extracellular vesicles from the cells chased for 30 min, but not from the cells chased for 4 hr. Insets: monomeric
Figure 2 continued on next page
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gold could be observed in association with extracellular vesicles in the cells that had been chased
for 30 min, but not in the cells that had been chased for 4 hr, indicating that the vesicles are endoso-
mal in origin. Third, we labelled non-permeabilised cells with an antibody against CD63, which has
been shown to be enriched on both ILVs and exosomes (Pols and Klumperman, 2009), and saw
strong labelling of the extracellular vesicles in the BafA1-treated cells, but little or no surface label-
ling in control cells (Figure 2B). Fourth, as shown in Figure 1, both the extracellular vesicles and the
ILVs of BafA1-treated cells are enriched in cholesterol, while cholesterol is largely absent from the
plasma membrane. Together, these observations indicate that the extracellular vesicles that accumu-
late in BafA1-treated cells are indeed exosomes.
When we quantified the number of exosomes at the plasma membrane, we found that they were
almost non-existent in control HeLa cells, but were very abundant (~5–8 exosomes per mm plasma
membrane) after prolonged treatment with BafA1 (Figure 2C,D, Figure 2—figure supplement 1).
We also used a biochemical approach to investigate exosome release, by collecting culture medium
from control and BafA1-treated cells and centrifuging it first at 10,000xg (which enriches for larger
particles like plasma membrane-derived vesicles and apoptotic bodies) and then at 100,000xg (which
enriches for exosomes). Western blots probed with an antibody against CD63 showed that the
marker was barely detectable in the fractions from control cells, but extremely abundant in the
100,000xg pellet from BafA1-treated cells (Figure 2E), consistent with our EM observations. We also
probed the exosome-enriched preparations for other extracellular vesicle markers, including Alix,
Tsg101, and CD9 (Figure 2—figure supplement 2), and in most cases, we saw at least a slight effect
of BafA1 treatment. However, Western blotting is not the most precise way of quantifying differen-
ces in protein concentration, and in future we intend to use mass spectrometry for more accurate
and comprehensive analyses.
The BafA1-induced exosomes are often in close proximity to the non-constricted clathrin-coated
pits that we described in our previous study (e.g., see the arrow in Figure 2C), and we speculated
that there might be a temporal relationship between exosome release and clathrin-coated pit forma-
tion, with frequent fusion events followed by a burst of clathrin recruitment. To investigate this rela-
tionship further, we cotransfected cells with GFP-tagged CD63 and mCherry-tagged clathrin light
chain. Live-cell TIRF imaging of BafA1-treated cells showed that under these conditions, clathrin is in
fact very static and fusion events are relatively rare. However, when fusions do occur, the CD63-GFP
signal persists rather than diffusing into the medium, and the ventral surface of the cell is decorated
with stable CD63-GFP puncta of varying intensities (Figure 2F). The frequency of exosomes in thin
sections of BafA1-treated cells, compared with the rarity of CD63-GFP fusion events, indicates that
the exosomes are somehow tethered to the plasma membrane, rather than released as diffusible
vesicles. We have previously hypothesised that ILVs are held together inside endosomes by an
unknown material that can be observed by electron microscopy (Edgar et al., 2014). Careful analysis
Figure 2 continued
gold could be found within MVBs from cells chased for 30 min (arrows), and aggregated within lysosomes from cells chased for 4 hr (arrowhead). Scale
bar: 200 nm. (B) DMSO- or BafA1-treated HeLa cells (100 nM, 16 hr) were surface-labelled with an antibody against the CD63 lumenal domain to
identify exosomes. Scale bar: 500 nm. (C) HeLa cells were treated with DMSO or BafA1 (100 nM, 16 hr) before being fixed and prepared for
conventional EM. Exosomes were often associated with clathrin-coated pits (arrow). Scale bar: 500 nm (D) The number of exosomes per mm of plasma
membrane was quantified. Data shown are means from three independent experiments, ± S.E.M. ***p<0.001 (E) Culture supernatants were collected
from mock-treated and BafA1-treated HeLa cells (100 nM, 16 hr), and centrifuged first at 10,000xg and then at 100,000xg. Western blots of the pellets
were probed with anti-CD63. (F) Total internal reflection fluorescence microscopy (TIRF) was performed on HeLa cells transiently expressing both CLC-
mCherry and CD63-GFP, following BafA1 treatment (100 nM, 16 hr). Representative stills are shown. Scale bar: 10 mm. (G) Conventional EM of BafA1-
treated cells (100 nM, 16 hr), with arrowheads indicating proteinacious material on exosomes. Scale bars: 500 nm. See also Figure 2—figure
supplement 1, 2.
DOI: 10.7554/eLife.17180.005
The following figure supplements are available for figure 2:
Figure supplement 1. Prolonged treatment with BafA1 induces exosome release.
DOI: 10.7554/eLife.17180.006
Figure supplement 2. Exosome-enriched preparations probed with antibodies against various extracellular vesicle markers.
DOI: 10.7554/eLife.17180.007
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showed that exosomes released from BafA1-treated cells display a similar material, which may cross-
link them together (Figure 2G).
Tetherin links exosomes to the plasma membrane
One candidate for a protein that might attach exosomes both to the plasma membrane and to each
other is tetherin, also called Bst2, CD317, and HM1.24. Tetherin is an interferon-inducible Type II
transmembrane protein with a GPI anchor at its C terminus. It acts to inhibit the spread of certain
enveloped viruses, including HIV, by cross-linking the virions and holding them together at the
plasma membrane (Neil et al., 2008). We speculated that tetherin might act in a similar manner on
exosomal vesicles (Figure 3A).
Immunofluorescence labelling of permeabilised cells showed that endogenous tetherin in HeLa
cells is localised to a juxtanuclear compartment, both under control conditions and after BafA1 treat-
ment (Figure 3B). This tetherin labelling colocalised with CD63 labelling, indicating that the juxtanu-
clear compartment is endosomal (Figure 3—figure supplement 1A). In non-permeabilised cells,
where the antibody was only able to access the cell surface, there was relatively little tetherin label-
ling under control conditions, but BafA1 treatment caused an increase in surface tetherin labelling
(Figure 3B). Again, there was excellent colocalisation between tetherin and CD63 (Figure 3—figure
supplement 1B). Pre-embedding EM labelling of BafA1-treated cells revealed that this surface label-
ling was concentrated on exosomes (Figure 3C, Figure 3—figure supplement 2).
However, the presence of tetherin on exosomes after BafA1 treatment does not necessarily mean
that tetherin stabilises the association of exosomes with the plasma membrane. Tetherin is known to
be trafficked through the endocytic pathway (Neil et al., 2008; Habermann et al., 2010), and thus
would be released following endosome-plasma membrane fusion even if it were not playing an
active role in exosome aggregation. In order to determine whether tetherin actually holds exosomes
together, we used CRISPR/Cas9-mediated genome editing to knock out the tetherin gene in HeLa
cells. Clonal cell lines were assayed by Western blotting, and a cell line in which tetherin was no lon-
ger expressed was selected for further studies (Figure 3D).
To investigate the effect of tetherin loss on exosome distribution, EM was performed on control
HeLa cells and on our knockout cell line, following BafA1 treatment. We observed fewer exosomes
in the tetherin knockout cells, and those that we did find appeared to be less aggregated
(Figure 3E). Quantification of three independent experiments revealed a ~4-fold decrease in exo-
somes at the plasma membrane in the tetherin knockout cells compared with controls (Figure 3F).
We also probed Western blots of exosome-enriched preparations from the culture supernatant of
control and tetherin knockout cells, treated with or without BafA1, to see whether the decrease in
exosomes at the plasma membrane could be correlated with an increase in the discharge of exo-
somes into the medium. There was a weak signal for CD63 in the knockout cells even without BafA1
treatment, and a strong increase in the signal from BafA1-treated tetherin knockout cells compared
with BafA1-treated wild-type cells (Figure 3G). Quantification of the signal from three experiments
showed a ~4-fold increase, in agreement with our EM results. We also probed for three other extra-
cellular vesicle-associated proteins, Alix, Tsg101, and CD9 (Figure 3—figure supplement 3). We
found that the tetherin knockout appeared to have a weak effect on Alix and Tsg101, and a stronger
effect on CD9. Again, it will be important to confirm and extend these observations by mass
spectrometry.
To obtain a three-dimensional view of exosomes associated with the plasma membrane, we per-
formed scanning electron microscopy on wild-type and tetherin knockout cells (Figure 4). In
untreated wild-type cells, the plasma membrane was essentially devoid of extracellular vesicles, sup-
porting our TEM analysis. Following BafA1-treatment, wild-type cells displayed extracellular vesicles
that were not randomly distributed, but rather appeared in clusters. There were also extracellular
vesicles associated with the plasma membrane of tetherin knockout BafA1-treated cells, but they
were less abundant and the clusters were generally smaller. By combining scanning EM with immu-
nogold labeling, we were able to visualize the surface distribution of both cholesterol (using TNF-BF)
(Figure 5A) and tetherin (Figure 5B). Both were found to be scattered evenly over the surface of
untreated cells, but to localize to exosome clusters after BafA1 treatment.
Tetherin has been proposed to function by using its transmembrane domain and its GPI anchor
to insert itself into two apposing membranes, the plasma membrane and the viral envelope, and
removal of the GPI anchor has been shown to abolish its ability to sequester viruses (Neil et al.,
Edgar et al. eLife 2016;5:e17180. DOI: 10.7554/eLife.17180 7 of 19
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2008) (see Figure 3A). To investigate whether tetherin uses the same strategy to attach exosomes
to the plasma membrane and to each other, we transiently transfected tetherin knockout HeLa cells
with either wild-type tetherin or a 4GPI mutant, both tagged with HA. Expression of the two con-
structs was confirmed by probing Western blots with an antibody against the HA tag (Figure 6—fig-
ure supplement 1). The wild-type tetherin construct was found to rescue the knockout phenotype,
Figure 3. Tetherin localises to exosomes and facilitates exosome tethering. (A) Schematic diagram of tetherin. (B) Mock-treated or BafA1-treated HeLa
cells (100 nM, 16 hr) were either permeabilised or left intact and stained with an anti-tetherin antibody. Scale bars: 20 mm. (C) Mock-treated or BafA1-
treated HeLa cells (100 nM, 16 hr) were surface-labelled using an anti-tetherin antibody followed by 10 nm protein A-gold. Scale bar: 500 nm. (D) The
tetherin gene was knocked out using CRISPR/Cas9, and the loss of tetherin in a clonal population was confirmed by Western blotting. (E) Wild-type or
tetherin-knockout HeLa cells were treated with BafA1 (100 nM, 16 hr) and processed for EM to analyse exosome frequency. Scale bar: 500 nm. (F) The
frequency of exosomes per mm plasma membrane in BafA1-treated (100 nM, 16 hr) wild-type or tetherin-knockout cells was calculated. The mean ± S.E.
M are shown from three independent experiments. ***p<0.001. (G) Exosome-enriched preparations were generated from the culture supernatants of
both wild-type and tetherin-knockout cells, either with or without BafA1-treatment (100 nM, 16 hr), and Western blots were probed with anti-CD63. See
also Figure 3—figure supplements 1, 2, 3.
DOI: 10.7554/eLife.17180.008
The following figure supplements are available for figure 3:
Figure supplement 1. Tetherin and CD63 colocalise in mock-treated and BafA1-treated cells.
DOI: 10.7554/eLife.17180.009
Figure supplement 2. Quantification of surface labeling.
DOI: 10.7554/eLife.17180.010
Figure supplement 3. Exosome-enriched preparations probed with antibodies against other extracellular vesicle markers.
DOI: 10.7554/eLife.17180.011
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and the clusters of exosomes on the cell surface
were heavily decorated with anti-HA. In contrast,
the 4GPI mutant failed to rescue the phenotype:
exosomes were scarce, and the construct local-
ised to the entire plasma membrane (Figure 6A).
In both cases, however, there was strong labeling
of the lumen of MVBs, indicating that tetherin
does not need its GPI anchor to be sorted into
ILVs (Figure 6B).
Finally, to extend our findings to a more physi-
ological system and to ensure that the tethering
we observe in HeLa cells is not due to endosome
acidification defects, we investigated EBV-trans-
formed B cell lines. These cells have been shown
to generate exosomes at steady state without a
stimulus (Raposo et al., 1996). We observed not
only clustering of exosomes by conventional EM
(Figure 7A), but also tetherin labeling on the
clustered exosomes and on ILVs by cryo immuno
EM (Figure 7B).
Discussion
In the present study, we have shown that
V-ATPase is a key regulator of both cholesterol
trafficking and endosome fate, with a dramatic
increase in plasma membrane-associated exo-
somes when V-ATPase is inhibited by BafA1. We
have also shown that these exosomes are
attached to the plasma membrane and to each
other by the antiviral protein tetherin.
Our findings on cholesterol trafficking abso-
lutely depended upon being able to localise cho-
lesterol at the ultrastructural level, using TNM-BF
as a probe. We found that there is practically no
cholesterol associated with the plasma mem-
brane after V-ATPase inhibition; instead, the cho-
lesterol is associated with extracellular vesicles, a
distinction that was not apparent by light micros-
copy. There are still a number of unanswered
questions about the connection between
V-ATPase and cholesterol, including precisely
how endosomal pH affects cholesterol trafficking. The availability of TNM-BF as an EM-compatible
cholesterol probe should allow these and other questions to be addressed.
Exosomes are not the only type of extracellular vesicles produced by cells; other types include
microvesicles, produced by plasma membrane shedding, and apoptotic bodies, produced by a con-
trolled ’explosion’ of cells undergoing apoptosis. Hence, there is some confusion in the literature
because not all studies purporting to be about exosomes actually distinguished between different
types of extracellular vesicles (Raposo and Stoorvogel, 2013). We used several criteria to confirm
the identity of the vesicles we observed, including similarity in size to ILVs (the other types of vesicles
are generally larger and more heterogeneous), the presence of a previously endocytosed tracer, and
enrichment of cholesterol and CD63. The connection between V-ATPase inhibition and exosome
production is at present unclear, and indeed, little is known about the machinery involved in endo-
some-plasma membrane fusion in general, in part because such fusion events are rare in most cell
types. Our finding that endosome-plasma membrane fusion can be induced by blocking endosome
acidification should facilitate the discovery of some of the players in this event.
Figure 4. Scanning electron microscopy reveals
clustering of exosomes on the cell surface. Wild-type
and tetherin-knockout cells were treated with or
without BafA1 (100 nM, 16 hr) before being fixed and
prepared for scanning electron microscopy. Scale bar:
1 mm.
DOI: 10.7554/eLife.17180.012
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Although exosomes are generally thought of as free extracellular vesicles, our live cell imaging
results and EM images, together with published micrographs of B cell exosomes (Raposo et al.,
1996; Simons and Raposo, 2009), suggested to us that exosomes can have an alternative fate: to
stay closely associated with the cell that produced them. We decided to investigate the potential
role of tetherin in this association, because we were struck by the similarity between our images of
exosomes in BafA1-treated cells, and published images of HIV-1 budding from cells in which tetherin
was overexpressed and the tetherin antagonist, Vpu, deleted from the viral genome (Neil et al.,
2008). We discovered that both endogenous and tagged tetherin localise to exosomes, that
Figure 5. Immuno-SEM reveals the localization of cholesterol and tetherin in 3D. HeLa cells treated with or without BafA1 (100 nM, 16 hr) were fixed,
surface-labelled, and viewed by scanning electron microscopy. The cells in A were probed for cholesterol and the cells in B were probed for tetherin.
Small ‘bumps’ observed on the plasma membrane probably represent surface-bound antibody complexes. Scale bars: 1 mm.
DOI: 10.7554/eLife.17180.013
Edgar et al. eLife 2016;5:e17180. DOI: 10.7554/eLife.17180 10 of 19
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Figure 6. Exosome tethering can be rescued by WT-tetherin, but not by DGPI-tetherin. (A) Tetherin-knockout cells were transiently transfected with WT-
tetherin-HA or DGPI-tetherin-HA, treated with BafA1 (100 nM, 16 hr), and prepared for surface labelling EM. Cells expressing tetherin-HA constructs
were identified by surface gold labelling using an anti-HA antibody. Scale bars: 500 nm. (B) Tetherin-knockout HeLa cells were transiently transfected
with either WT-tetherin-HA or DGPI-tetherin-HA constructs. Cryosections of both were immunolabelled with anti-HA antibodies, revealing localisation
to the ILVs of MVBs. Scale bars: 200 nm. See also Figure 6—figure supplement 1.
Figure 6 continued on next page
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knocking out tetherin strongly reduces the number of exosomes associated with the plasma mem-
brane with a concomitant increase in exosomes released into the medium, and that this phenotype
can be rescued by wild-type tetherin but not by a tetherin construct lacking a GPI anchor, which is
also incapable of tethering virus particles. One difference between exosomes and viruses is that
whereas overexpression of tetherin in virally infected cells leads to a massive accumulation of virions
at the plasma membrane (Neil et al., 2008), overexpression of tetherin in BafA1-treated cells did
not produce any marked increase in exosome frequency. This may be because the unit number of
exosomes is limited by the number of ILVs per endosome, whereas cells infected with a virus such as
HIV-1 are programmed to bud as many viruses as possible from the plasma membrane, and so are
less confined by space and membrane availability.
A single endosome can generate ILVs via distinct mechanisms, resulting in a heterogeneous pop-
ulation of vesicles (Edgar et al., 2014). If the endosome then fuses with the plasma membrane, all of
the vesicles will be discharged; however, the ultimate fate of each vesicle may depend upon whether
or not it contains tetherin. The presence of a GPI anchor suggests that tetherin may preferentially
insert into the most cholesterol-rich vesicles; however, in order for tetherin to tether vesicles to each
other as well as to the plasma membrane, it must be able to insert into the vesicles both via its GPI
anchor and via its transmembrane domain (see Figure 3A) (Venkatesh and Bieniasz, 2013). In any
case, a non-homogenous distribution of tetherin would provide the cell with a mechanism for keep-
ing some vesicles attached the cell surface while releasing others into the extracellular matrix or
fluid. In addition, expression of tetherin is tightly regulated. It is most highly expressed in cells of the
immune system (Ishikawa et al., 1995; Goto et al., 1994; Blasius et al., 2006) but even in cells
where it is normally undetectable, its expression can be dramatically upregulated by interferon
(Goto et al., 1994; Blasius et al., 2006). This tight control of tetherin expression may provide a
means whereby the cell can regulate the fate of its exosomes, and thus control whether the exo-
somes engage in local interactions (e.g., antigen presentation via an immunological synapse
[Raposo et al., 1996]) or long-distance interactions (e.g., supporting or inhibiting cell migration
[Sung et al., 2015]). Supporting this notion, tetherin has recently been shown to promote dendritic
cell activation and antigen presentation via MHC class II (Li et al., 2016), a pathway that has been
shown to be mediated by exosomes (Raposo et al., 1996).
There is currently great interest in exosomes as vehicles for intercellular communication, and clini-
cal studies are underway to exploit them both as diagnostic tools and as potential therapeutic
agents. However, as several recent review articles have pointed out, we still don’t really know what
exosomes contain, because there is no way of specifically purifying them. In previous work from our
lab on clathrin-coated vesicles (CCVs), we have shown that even with an impure preparation, we can
deduce the protein composition by comparative proteomics (e.g., by preparing the CCV fraction
from control vs. clathrin-depleted cells [Borner et al., 2012]). The present study demonstrates that
one can specifically enrich or deplete exosomes from the extracellular fluid by manipulating endoso-
mal pH and/or tetherin levels. Thus, by comparing exosome-enriched fractions prepared from cells
treated in different ways, it should be possible to determine which proteins in the fraction are actu-
ally exosome components and which are contaminants.
Exosomes have been proposed to act as shuttles for the spread and propagation of prions
(Fevrier et al., 2004), beta amyloid (Rajendran et al., 2006), and alpha-synuclein (Danzer et al.,
2012), all of which can lead to severe neurodegenerative disorders. A number of enveloped viruses,
including HIV-1, have developed ways of keeping tetherin off the plasma membrane, and one of the
consequences of this downregulation may be that exosome interactions are altered in infected cells.
Interestingly, HIV-1-infected patients display an increased propensity to develop neurodegenerative
disorders (HAND – HIV-1 Associated Neurodegeneration), as well as increased beta amyloid
(Achim et al., 2009) and alpha-synuclein deposition (Khanlou et al., 2009). Exosomes have also
Figure 6 continued
DOI: 10.7554/eLife.17180.014
The following figure supplement is available for figure 6:
Figure supplement 1. Western blotting of tetherin rescue cells.
DOI: 10.7554/eLife.17180.015
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been shown to play a pathological role in cancer. Tumor cells frequently shed excessive amounts of
exosomes, and these are thought to promote the growth, survival, and metastasis of the tumor in a
number of ways (Zhang and Wang, 2015; Zhang et al., 2015; Ono et al., 2014; Melo et al., 2014;
Anastasiadou and Slack, 2014; Zhao et al., 2016). Interferon-a is sometimes given as a chemother-
apeutic drug, and it is tempting to speculate that one of its mechanisms of action may be to prevent
exosome shedding, by upregulating tetherin expression in the tumor cells. Thus, the importance of
tetherin in health and disease is likely to extend well beyond its role as an antiviral protein.
Figure 7. EBV-transformed B cells display clusters of tetherin-positive exosomes. (A) 721.221 EBV-transformed B cells were prepared for conventional
EM. Clusters of exosomes can be seen at the cell surface. Scale bars: 500 nm. (B) Immuno-EM reveals that the clustered exosomes and the ILVs of
MVBs are positive for tetherin labeling. Scale bars: 500 nm.
DOI: 10.7554/eLife.17180.016
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Materials and methods
Cell culture
HeLa cells were a gift from Paul Lehner (University of Cambridge, UK) and were cultured in DMEM
supplemented with 10% fetal bovine serum, L-glutamine, and Penicillin/Streptomycin, in 5% CO2 at
37˚C. The CD63-GFP construct was a gift from Paul Luzio (University of Cambridge, UK), the CLC-
mCherry construct was made in-house, and the tetherin-HA constructs were as described
(Billcliff et al., 2013). Transient transfections were performed using TransitIT-HeLa MONSTER
(Mirus).
Tetherin knockout HeLa cells were generated using the CRISPR/Cas9 method. Guide RNAs tar-
geting a sequence within the first exon of the tetherin gene (5’-GCTCCTGATCATCGTGATTCTGG)
were cloned into pX330 (Addgene plasmid #42230). Monoclonal HeLa cell lines were generated and
assayed for expression of the tetherin protein by immunofluorescence and Western blotting. An
apparent tetherin negative line was selected, and the absence of wild-type tetherin sequence was
confirmed by PCR-cloning and Sanger sequencing of the targeted region.
The EBV-transformed B cell line (721.221) was a gift from Gillian Griffiths (University of Cam-
bridge, UK) and were cultured in RPMI supplemented with 10% fetal bovine serum, L-glutamine, and
Penicillin/Streptomycin, in 5% CO2 at 37˚C.
All cells were free of mycoplasma.
Antibodies
Antibodies used for immunofluorescence included a mouse monoclonal anti-CD63, IB5 (a gift from
Mark Marsh, UCL, UK), rabbit polyclonal anti-BODIPY (A-5770, Molecular Probes - RRID:AB_
2536193), rabbit polyclonal anti-Bst2/tetherin (NIH AIDS reagent program), and a mouse monoclonal
antibody against tetherin, HM1.24 (Goto et al., 1994). For Western blotting, the following antibod-
ies were used: a mouse polyclonal anti-tetherin antibody, B02P (Abnova, Taiwan - RRID:AB_
1137604), a mouse monoclonal antibody against the HA tag (Covance, 16B12 - RRID:AB_10064220),
a goat polyclonal anti-EF2 antibody (Santa Cruz, C-14 - RRID:AB_640040), a rabbit polyclonal anti-
Alix antibody (a gift from Harald Stenmark, University of Oslo, Norway), a mouse monoclonal anti-
Tsg101 antibody (GeneTex - RRID:AB_373239), a rabbit monoclonal anti-CD9 antibody (Abcam,
ab92726 - RRID:AB_10561589) and a rabbit polyclonal anti-clathrin antibody (made in-house
[Simpson et al., 1996]). A rabbit anti-mouse IgG antibody (Dako) was used as a bridging antibody
for immuno-EM.
Reagents
Magic Red-Cathepsin B (ICT938, BioRad) and Lysotracker Red DND-99 (L7528, ThermoFisher) were
used for live cell imaging. Filipin complex (F9765, Sigma) was dissolved in DMSO, and used at a
25 mg/ml. TNM-BF was synthesized as described previously (Nishimura et al., 2010). Protocols for
labeling are detailed below. Methyl-b-cyclodextrin (C4951, Sigma-Aldrich) was dissolved in water
and used at a final concentration of 10 mM for 30 min. BafA1 (B1793, Sigma-Aldrich) was dissolved
in DMSO and used at a final concentration of 100 nM. Control experiments were performed using
equal volumes of DMSO. Cell viability with and without bafilomycin treatment was assessed by try-
pan blue exclusion staining, and in both cases it was found to be >98%.
Immunofluorescence
Cells were fixed with 4% PFA/PBS and permeabilised using 0.1% saponin. Blocking and subsequent
steps were performed with 1% BSA, 0.01% saponin in PBS. Cells were mounted on slides with
mounting medium containing DAPI (Invitrogen).
Filipin and TNM-BF double labeling immunofluorescence
Cells were fixed with 4% PFA. They were initially stained with filipin, before being permeabilised
with 0.1% saponin, blocked with 1% BSA, 0.01% saponin in PBS, and stained with 1 mM TNM-BF for
30 min on ice. The cells were washed with PBS before being mounted on slides with mounting
medium (Invitrogen), and visualized using a Zeiss 880 confocal microscope and 63X objective.
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Western blotting
Western blotting for tetherin and for CD63 was performed in non-reducing conditions and tetherin
blots using a sample buffer without bromophenol blue (10% SDS, 15% glycerol, 0.2 M Tris-HCl pH
6.8) as previously described (Giese and Marsh, 2014). Other Western blots were performed accord-
ing to standard protocols. Signals were quantified using ImageJ. Exosome-enriched preparations
were generated from cell culture supernatants as previously described (The´ry et al., 2006). Cells
were grown in equal numbers on 245 mm x 245 mm dishes in 60 ml of media. Supernatants were
collected and cells removed by a low speed spin (300xg, 10 min). Pellets were discarded and super-
natants were then spun to remove large cell debris (2000xg, 10 min). Again pellets were discarded
and supernatants were ultracentrifuged (Type 70 Ti Rotor, Beckman Coulter) to remove smaller cell
debris (10,000xg, 30 min). Pellets were retained for controls and supernatants were again collected
and ultracentrifuged (Type 70 Ti Rotor, Beckman Coulter) at 100,000xg for 70 min. Pellets were
washed in PBS and repelleted at 100,000xg for 70 min (Type 70 Ti Rotor, Beckman Coulter) to give
exosome-enriched fractions. Exosome-enriched pellets were resuspended in 100 ml sample buffer
and equal volumes loaded for Western blotting. Quantification of Western blotting was performed
using ImageJ.
Cryo-immuno electron microscopy
Cells were fixed with 4% PFA, 0.2% glutaraldehyde, 0.1 M phosphate buffer (pH 7.4). They were
then pelleted in 12% gelatine and 70 nm sections cut at  120˚C with a Leica ultracut UCT ultrami-
crotome. Sections were labelled with 10 nm protein-A gold (Utrecht university, the Netherlands) and
stained as previously described (Slot et al., 1991).
Cryo-immuno electron microscopy to localise cholesterol
Control or BafA1-treated HeLa cells (100 nM, 16 hr) were fixed with 4% PFA, 0.2% glutaraldehyde,
0.1 M phosphate buffer (pH 7.4). Cells were pelleted in 12% gelatine and 70 nm sections cut at
 120˚C with a Leica ultracut UCT ultramicrotome. Sections were picked up in 2.3 M sucrose and
grids were blocked with 2% gelatin. Prior to gold labeling, grids were washed with 15 mM glycine
and then washed twice with PBS. Sections were incubated on drops of 1 mM TNM-BF for 30 min on
ice, washed, blocked with 1% BSA in PBS, and then incubated with a rabbit polyclonal anti-BODPIY
antibody (Molecular Probes, Invitrogen, UK). Sections were labelled with 10 nm protein-A gold
(Utrecht university, the Netherlands) and stained as previously described (Slot et al., 1991).
Conventional electron microscopy
HeLa cells were grown on 13 mm diameter Thermanox coverslips (Nalge Nunc International, Roches-
ter, NY,) and briefly fixed in their culture medium with an equal volume of double strength fixative
(4% PFA, 5% glutaraldehyde, 0.1 M cacodylate buffer pH 7.4), before being exchanged for single
strength fixative (2% PFA, 2.5% glutaraldehyde in 0.1 M cacodylate buffer pH 7.4). EBV-transformed
B cells were briefly fixed in a double strength fixative (4% PFA, 5% glutaraldehyde, 0.1 M cacodylate
buffer pH 7.4) at an equal volume to their culture medium before being spun into a pellet. Cells
were post-fixed with 1% osmium tetroxide and incubated with 1% tannic acid to enhance contrast.
They were dehydrated using increasing concentrations of ethanol before being embedded onto
EPON stubs (coverslips) or EPON-filled molds (pellets), and cured overnight at 65˚C. Coverslips
were removed using a heat-block. Ultrathin 70 nm conventional sections were cut using a diamond
knife mounted to a Reichart ultracut S ultramicrotome. Sections were stained with lead citrate before
being observed on a FEI Tecnai transmission electron microscope (FEI, the Netherlands) at an oper-
ating voltage of 80 kV.
Correlative Light and Electron Microscopy (CLEM)
Cells were grown on gridded glass coverslips (MatTek Corporation, Ashland, MA). Immunofluores-
cence staining was performed as described above, following which cells were refixed with 2% PFA,
2.5% glutaraldehyde, 0.1 M cacodylate and processed for conventional EM. Resin stubs were
inverted over areas of interest and baked overnight. Coverslips were subsequently removed using
liquid nitrogen.
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Pre-embedding surface labeling of cell surface/exosomal antigens
Cells were grown on Thermanox coverslips (Nalge Nunc International, Rochester, NY) and briefly
fixed with 4% PFA/0.1 M cacodylate at a 1:1 ratio with culture medium. After 2 min, fixative was
replaced with fresh 2% PFA/0.1 M cacodylate. Cells were blocked with 1% BSA, 0.1% Aurion BSA
(Aurion, the Netherlands) before being incubated with mouse monoclonal antibodies against
lumenal/extracellular antigens for 1 hr at room temperature, followed by incubation with a rabbit
anti-mouse secondary antibody (Dako). The cells were then labeled with 10 nm protein-A gold
(Utrecht university, the Netherlands), and re-fixed with 2% PFA, 2.5% glutaraldehyde / 0.1 M cacody-
late, before being post-fixed with 1% osmium tetroxide and processed for conventional resin
embedding as above. For cell surface cholesterol labeling, cells were fixed as above. Coverslips
were then incubated with 1 mM TNM-BF for 30 min on ice, washed, and incubated with a rabbit
polyclonal anti-BODIPY antibody followed by 10 nm protein-A gold as above.
BSA-gold feeding
BSA conjugated to 5 nm colloidal gold was prepared as previously described (Slot and Geuze,
1985). Cells were incubated with BSA-gold for 10 min, followed by five washes with PBS to remove
surface BSA-gold. The cells were then chased in fresh medium for either 30 min or 4 hr to load
endosomes or lysosomes respectively, before addition of BafA1 (100 nM, 16 hr). Cells were then
fixed for conventional electron microscopy (as above).
Quantification of exosomes per unit plasma membrane
Exosomes were counted manually and lengths of plasma membrane calculated using ImageJ. Five
consecutive photographs along random portions of plasma membrane were imaged, from at least
five random cells – omitting areas where cells were within 5 mm of another cell. Only exosomes
within 500 nm of plasma membrane were quantified. Three independent experiments were
performed.
Quantification of surface labeling immuno gold density
The number of gold particles associated with plasma membrane or extracellular vesicles per image
were counted. The length of plasma membrane (mm) per image was then calculated using ImageJ
and the number of gold particles per mm were calculated for each image. Over 100 mm total plasma
membrane was quantified per condition, over two separate experiments.
Scanning EM
Cells grown on glass coverslips were fixed with 2% PFA/ 2.5% glutaralydehyde, 0.1 M cacodylate
and secondarily fixed with 1% osmium. After critical point drying, the cells were coated with 15 nm
of carbon using a Quorum Q150 carbon coater and imaged with a FEI Verious 460 SEM.
Immuno-SEM
Cells were grown on glass coverslips and fixed with 4% PFA in PBS. Coverslips were labeled with
gold as described above (pre-embedding surface labeling of cell surface/exosomal antigens). After
gold labeling, cells were refixed with 2% PFA, 2.5% glutaraldehyde, and sputter coated with a thin
layer of carbon using a Quorum Q150 carbon coater. SEM images were collected using an FEI Vari-
ous 640 SEM. A secondary detector was used to acquire cell surface images, immediately followed
by acquisition using a backscatter detector to detect gold particles.
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